Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women’s health, cancer, and organ health. Natera’s proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| NTRA | Natera, Inc. | 2025-10-30 18:13:34 | 196.18 | 2.96 | 1.53 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NTRA | 0001604821 | Natera, Inc. | US6323071042 | — | 010894487 | Nasdaq | 8071 | Services-Medical Laboratories | 1231 | DE | 13011 MCCALLEN PASS | AUSTIN | TX | 78753 | UNITED STATES | US | 650-249-9090 | 13011 MCCALLEN PASS, AUSTIN, TX, 78753 | 13011 MCCALLEN PASS, AUSTIN, TX, 78753 | — | Genetic testing | 2004 | Steve Chapman | 3,018 | https://natera.com | 13,150,000,000 | 136,757,000 | 137,248,106 | Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women’s health, cancer, and organ health. Natera’s proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas. | 2025-10-30 12:35:48 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 13,150,000,000 | 7,890,000,000 | 150 | 135,186,184 | 14,428,307 | 11.9481 |
| 2023 | 5,260,000,000 | 2,690,000,000 | 104.6693 | 120,757,877 | 7,472,202 | 6.5959 |
| 2022 | 2,570,000,000 | -6,760,000,000 | -72.4544 | 113,285,675 | 17,814,777 | 18.6599 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Solomon Moshkevich | President | 2024 | 490,032 | — | 4,103,350 | 285,574 | 9,900 | 4,888,856 |
| Matthew Rabinowitz | Executive Chairman | 2024 | 401,484 | — | 9,027,579 | 405,066 | 0 | 9,834,129 |
| Steven Chapman | Chief Financial Officer, President, Chief Executive Officer | 2024 | 799,948 | — | 11,284,474 | 938,352 | 9,900 | 13,032,674 |
| John Fesko | Chief Business Officer, President | 2024 | 490,032 | — | 4,103,350 | 285,574 | 9,900 | 4,888,856 |
| Daniel Rabinowitz | Chief Legal Officer | 2023 | 407,594 | — | 2,715,379 | 193,112 | 9,900 | 3,325,985 |
| Fiscal Year | Employee Count |
|---|---|
| 2020 | 1,815 |
| 2019 | 1,039 |
| 2018 | 975 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 1,696,911,000 | 1,082,571,000 | 820,222,000 |
| Cost Of Revenue | 672,304,000 | 588,564,000 | 453,632,000 |
| Gross Profit | 1,023,158,000 | — | — |
| Research And Development Expenses | 404,138,000 | 320,678,000 | 316,415,000 |
| General And Administrative Expenses | 841,314,000 | 618,307,000 | 588,591,000 |
| Operating Expenses | 1,919,205,000 | 1,528,816,000 | 1,361,262,000 |
| Operating Income | -222,294,000 | -446,245,000 | -541,040,000 |
| Net Income | -190,426,000 | -434,801,000 | -547,799,000 |
| Earnings Per Share Basic | -1.53 | -3.78 | -5.57 |
| Earnings Per Share Diluted | -1.53 | -3.78 | -5.57 |
| Weighted Average Shares Outstanding Basic | 124,718,000 | 114,997,000 | 98,408,000 |
| Weighted Average Shares Outstanding Diluted | 124,718,000 | 114,997,000 | 98,408,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 945,587,000 | 642,095,000 | 466,005,000 |
| Marketable Securities Current | 22,689,000 | 236,882,000 | 432,301,000 |
| Accounts Receivable | 314,165,000 | 278,289,000 | 244,385,000 |
| Inventories | 44,744,000 | 40,759,000 | 35,406,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 1,375,820,000 | 1,258,549,000 | 1,211,817,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 162,046,000 | 111,210,000 | 92,453,000 |
| Other Assets Non Current | 36,720,000 | 15,403,000 | 18,330,000 |
| Total Assets Non Current | 284,915,000 | 183,150,000 | 182,657,000 |
| Total Assets | 1,660,735,000 | 1,441,699,000 | 1,394,474,000 |
| Accounts Payable | 34,922,000 | 14,998,000 | 31,148,000 |
| Deferred Revenue | 19,754,000 | 16,612,000 | 10,777,000 |
| Short Term Debt | 80,362,000 | 80,402,000 | 80,350,000 |
| Other Liabilities Current | 146,893,000 | 149,405,000 | 144,214,000 |
| Total Liabilities Current | 344,045,000 | 307,274,000 | 310,499,000 |
| Long Term Debt | — | 282,945,000 | 281,653,000 |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 121,270,000 | 369,098,000 | 378,231,000 |
| Total Liabilities | 465,315,000 | 676,372,000 | 688,730,000 |
| Common Stock | 12,000 | 11,000 | 11,000 |
| Retained Earnings | -2,567,862,000 | -2,377,436,000 | -1,942,635,000 |
| Accumulated Other Comprehensive Income | -344,000 | -3,085,000 | -16,362,000 |
| Total Shareholders Equity | 1,195,420,000 | 765,327,000 | 705,744,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 30,968,000 | 24,097,000 | 16,702,000 |
| Share Based Compensation Expense | 274,428,000 | 191,808,000 | 152,384,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 35,876,000 | 33,904,000 | 124,081,000 |
| Change In Inventories | 3,985,000 | 5,353,000 | 8,257,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | 6,000 |
| Change In Accounts Payable | 13,210,000 | -15,458,000 | 5,462,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 135,664,000 | -246,955,000 | -431,501,000 |
| Purchases Of Marketable Securities | 122,010,000 | 98,303,000 | 86,947,000 |
| Sales Of Marketable Securities | 24,822,000 | 306,000,000 | 248,482,000 |
| Acquisition Of Property Plant And Equipment | 66,423,000 | 39,199,000 | 47,697,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 137,624,000 | 168,498,000 | 330,338,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 30,204,000 | 254,461,000 | 482,640,000 |
| Change In Cash | 303,492,000 | 176,004,000 | 381,477,000 |
| Cash At End Of Period | 945,587,000 | 642,095,000 | 466,005,000 |
| Income Taxes Paid | 1,307,000 | 295,000 | 549,000 |
| Interest Paid | 7,897,000 | 11,346,000 | 8,060,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -1.53 | -3.78 | -5.57 |
| Price To Earnings Ratio | -103.4641 | -16.5714 | -7.2118 |
| Earnings Growth Rate | -59.5238 | -32.1364 | 6.9098 |
| Price Earnings To Growth Ratio | 1.7382 | 0.5157 | -1.0437 |
| Book Value Per Share | 9.585 | 6.6552 | 7.1716 |
| Price To Book Ratio | 16.5154 | 9.4122 | 5.6013 |
| Ebitda | -147,466,000 | -397,771,000 | -521,229,000 |
| Enterprise Value | — | 6,924,664,080 | 3,849,047,360 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | 0.4748 | 0.5129 |
| Capital Expenditures | 81,804,000 | 42,854,000 | 43,639,000 |
| Free Cash Flow | 53,860,000 | -289,809,000 | -475,140,000 |
| Return On Equity | -0.1593 | -0.5681 | -0.7762 |
| One Year Beta | 1.5412 | 1.1247 | 1.6334 |
| Three Year Beta | 1.5276 | 1.5861 | 1.3767 |
| Five Year Beta | 1.3693 | 1.3865 | 1.4252 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Brophy Michael Burkes | Chief Financial Officer | 2029-06-23 | 12,500 | D | 37,500 |
| Brophy Michael Burkes | Chief Financial Officer | 2029-06-08 | 25,000 | D | 50,000 |
| Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | 2025-10-29 | 300 | D | 65,693 |
| Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | 2025-10-29 | 400 | D | 65,293 |
| Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | 2025-10-29 | 667 | D | 64,626 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| William F Hagerty, IV | Senator | 2021-05-04 | Sale (Partial) | 2021-04-20 | Self | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Josh Gottheimer | 2025-10-15 | NJ05 | Purchase | 2025-09-22 | Joint | $1,001 - $15,000 |
| Josh Gottheimer | 2025-09-05 | NJ05 | Purchase | 2025-08-22 | Joint | $1,001 - $15,000 |
| Josh Gottheimer | 2025-08-11 | NJ05 | Sale (Partial) | 2025-07-22 | Joint | $1,001 - $15,000 |
| Josh Gottheimer | 2024-12-05 | NJ05 | Purchase | 2024-11-20 | Joint | $1,001 - $15,000 |
| Daniel Goldman | 2023-05-19 | NY10 | Sale (Partial) | 2023-04-10 | — | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Envestnet Portfolio Solutions, Inc. | 2025-09-30 | 1,060,309 | 6,587 | 160.9699 |
| TrueMark Investments, LLC | 2025-09-30 | 1,068,519 | 6,638 | 160.97 |
| JENNISON ASSOCIATES LLC | 2025-09-30 | 54,779,486 | 340,309 | 160.9698 |
| TEACHER RETIREMENT SYSTEM OF TEXAS | 2025-09-30 | 2,734,720 | 16,989 | 160.97 |
| iA Global Asset Management Inc. | 2025-09-30 | 1,072,000 | 6,659 | 160.9851 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| PARNASSUS FUNDS | 2025-09-30 | Institutional Shares | PFPRX | 60,923 | 9,806,775.31 | 1.1587 |
| PARNASSUS FUNDS | 2025-09-30 | Investor Shares | PARNX | 60,923 | 9,806,775.31 | 1.1587 |
| WisdomTree Trust | 2025-08-31 | WisdomTree Efficient Gold Plus Equity Strategy Fund | GDE | 137 | 23,050.25 | 0.0077 |
| Global X Funds | 2025-08-31 | Global X Genomics & Biotechnology ETF | GNOM | 11,293 | 1,900,047.25 | 4.1242 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-08-31 | SIIT Multi-Asset Real Return Fund - Class A | SEIAX | 1,314 | 221,080.5 | 0.0292 |